Literature DB >> 1386609

A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease.

M C Sneller1, S E Straus, E S Jaffe, J S Jaffe, T A Fleisher, M Stetler-Stevenson, W Strober.   

Abstract

In mice, the two distinct autosomal recessive genes lpr and gld can induce a syndrome characterized by autoantibody formation and the progressive accumulation of an unusual CD4-CD8- T cell population in peripheral lymphoid tissue. This phenotype does not precisely mirror any human disease. In this report we describe two patients with a progressive lymphoproliferative disorder associated with autoimmunity. The peripheral blood and lymph nodes of these patients contained large numbers of an unusual CD4-CD8- T cell population. These CD4-CD8- T cells express surface markers characteristic of mature peripheral blood T cells (CD3, CD2, CD5), express the alpha/beta form of the T cell receptor, and do not express surface markers characteristic of immature thymocytes (CD1) or NK cells (CD16, CD56). Functionally, these cells exhibited deficient proliferation and lymphokine production upon stimulation with mitogenic antibodies to CD3 or CD2. Both proliferation and lymphokine production could be augmented by co-stimulation with an antibody directed at the CD28 determinant. The clinical and immunological features of this syndrome resemble the lymphoproliferative/autoimmune disease seen in lpr and gld mice.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1386609      PMCID: PMC443107          DOI: 10.1172/JCI115867

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  A monoclonal antibody that identifies human peripheral blood monocytes recognizes the accessory- cells required for mitogen-induced T lymphocyte proliferation.

Authors:  S A Rosenberg; F S Ligler; V Ugolini; P E Lipsky
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

2.  Recognition of cluster of differentiation 1 antigens by human CD4-CD8-cytolytic T lymphocytes.

Authors:  S Porcelli; M B Brenner; J L Greenstein; S P Balk; C Terhorst; P A Bleicher
Journal:  Nature       Date:  1989-10-05       Impact factor: 49.962

3.  Accessory cell independent proliferation of human T4 cells stimulated by immobilized monoclonal antibodies to CD3.

Authors:  T D Geppert; P E Lipsky
Journal:  J Immunol       Date:  1987-03-15       Impact factor: 5.422

4.  Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes.

Authors:  P Kisielow; H Blüthmann; U D Staerz; M Steinmetz; H von Boehmer
Journal:  Nature       Date:  1988-06-23       Impact factor: 49.962

5.  CS-A therapy in MRL-lpr/lpr mice: amelioration of immunopathology despite autoantibody production.

Authors:  J D Mountz; H R Smith; R L Wilder; J P Reeves; A D Steinberg
Journal:  J Immunol       Date:  1987-01-01       Impact factor: 5.422

6.  Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes.

Authors:  J J Weis; T F Tedder; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

Review 7.  The unfolding story of T cell receptor gamma.

Authors:  D M Pardoll; A M Kruisbeek; B J Fowlkes; J E Coligan; R H Schwartz
Journal:  FASEB J       Date:  1987-08       Impact factor: 5.191

8.  The fate of CD4-8- T cell receptor-alpha beta+ thymocytes.

Authors:  H I Levitsky; P T Golumbek; D M Pardoll
Journal:  J Immunol       Date:  1991-02-15       Impact factor: 5.422

9.  Specific antimononuclear phagocyte monoclonal antibodies. Application to the purification of dendritic cells and the tissue localization of macrophages.

Authors:  W C Van Voorhis; R M Steinman; L S Hair; J Luban; M D Witmer; S Koide; Z A Cohn
Journal:  J Exp Med       Date:  1983-07-01       Impact factor: 14.307

10.  Deletion of autospecific T cells in T cell receptor (TCR) transgenic mice spares cells with normal TCR levels and low levels of CD8 molecules.

Authors:  H S Teh; H Kishi; B Scott; H Von Boehmer
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

View more
  75 in total

1.  Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop.

Authors:  Joao B Oliveira; Jack J Bleesing; Umberto Dianzani; Thomas A Fleisher; Elaine S Jaffe; Michael J Lenardo; Frederic Rieux-Laucat; Richard M Siegel; Helen C Su; David T Teachey; V Koneti Rao
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

Review 2.  Death receptor signaling and autoimmunity.

Authors:  Richard M Siegel; Jagan Muppidi; Margaret Roberts; Melissa Porter; Zhengqi Wu
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 3.  New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome.

Authors:  David T Teachey
Journal:  Curr Opin Pediatr       Date:  2012-02       Impact factor: 2.856

4.  New take on comparative immunology: relevance to immunotherapy.

Authors:  Ena Wang; Adriana Albini; David F Stroncek; Francesco M Marincola
Journal:  Immunotherapy       Date:  2009-05       Impact factor: 4.196

5.  Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis.

Authors:  Julie E Niemela; Lianghao Lu; Thomas A Fleisher; Joie Davis; Iusta Caminha; Marc Natter; Laurel A Beer; Kennichi C Dowdell; Stefania Pittaluga; Mark Raffeld; V Koneti Rao; João B Oliveira
Journal:  Blood       Date:  2010-11-15       Impact factor: 22.113

Review 6.  Death receptors and caspases: role in lymphocyte proliferation, cell death, and autoimmunity.

Authors:  Sabine Adam-Klages; Dieter Adam; Ottmar Janssen; Dieter Kabelitz
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 7.  Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS).

Authors:  Pu Li; Ping Huang; Ye Yang; Mu Hao; Hongwei Peng; Fei Li
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

8.  FAS haploinsufficiency is a common disease mechanism in the human autoimmune lymphoproliferative syndrome.

Authors:  Hye Sun Kuehn; Iusta Caminha; Julie E Niemela; V Koneti Rao; Joie Davis; Thomas A Fleisher; João B Oliveira
Journal:  J Immunol       Date:  2011-04-13       Impact factor: 5.422

9.  Autoimmune lymphoproliferative syndrome presenting with glomerulonephritis.

Authors:  Hirokazu Kanegane; Maria Marluce dos Santos Vilela; Yue Wang; Takeshi Futatani; Hiroyoshi Matsukura; Toshio Miyawaki
Journal:  Pediatr Nephrol       Date:  2003-04-04       Impact factor: 3.714

10.  The technological transformation of patient-driven human immunology research.

Authors:  Helen C Su
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.